The popularity of Glucagon-like peptide 1 (GLP-1) agonists, drugs which mimic a hormone to stimulate insulin production, has drastically increased since the U.S FDA’s approval of Ozempic in 2017. These drugs can help control type two diabetes by lowering blood sugar when it rises, for example, after meals. However, despite their benefits, these drugs can cause several serious side effects, such as depression and suicidal thoughts. GLP-1’s are also extremely costly, with a monthly supply costing up to $1,350 in America.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
